Replimune

Replimune Group

The company develops oncolytic immunotherapies for cancer patients, including its first commercial treatment for adults with advanced melanoma.

Revolution Medicines

This clinical-stage biopharmaceutical company develops targeted therapies for patients with RAS-addicted cancers, including its approved treatment for metastatic pancreatic adenocarcinoma.

Humane Genomics

This company develops synthetic oncolytic viral therapies to treat cancer patients by engineering viruses that selectively infect and destroy malignant cells.

CMPI

This biopharmaceutical company develops cancer immunotherapies that activate the immune system to treat patients with advanced solid tumours, such as metastatic melanoma.

Stratosvir

This company develops viral immunotherapies for late-stage cancer patients to target solid tumours through systemic delivery and immune system activation.

Revealis Biotherapeutics

This company develops therapeutic cancer vaccines targeting immune-escaped and immunotherapy-resistant tumours for healthcare providers and patients.

Oncorus

This company develops intravenous self-amplifying RNA medicines and viral immunotherapies for patients with solid tumours.

Theolytics

The company develops oncolytic viral immunotherapies for patients with solid tumours.